SCHEMBL1638669

SCHEMBL1638669

COc1ccc(O)c(/C=N\NC(=O)c2cc(OC)ccc2O)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.64
MGAM O43451 3/20 0.64
KDM4E B2RXH2 3/20 0.64
GAA P10253 2/20 0.64
SI P14410 2/20 0.64
MGAM2 Q2M2H8 2/20 0.64
ATM Q13315 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
LMNA P02545 3/20 0.59
GUSB P08236 1/20 0.59
POLB P06746 4/20 0.57
NPC1 O15118 3/20 0.56
KMT2A Q03164 4/20 0.55
MEN1 O00255 3/20 0.55
HTT P42858 2/20 0.55
RAB9A P51151 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
PSMD14 O00487 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12767404 1.00 MAPT (0.64) MAPTMGAMKDM4EGAASI
SCHEMBL1638671 1.00 MAPT (0.64) MAPTMGAMKDM4EGAASI
SCHEMBL1637349 0.92 POLB (0.61) MAPTMGAMKDM4EGAASI
SCHEMBL1637351 0.92 POLB (0.61) MAPTMGAMKDM4EGAASI
SCHEMBL12767394 0.92 POLB (0.61) MAPTMGAMKDM4EGAASI
SCHEMBL1637739 0.91 GUSB (0.59) MAPTMGAMKDM4EGAASI
SCHEMBL1637667 0.91 MAPT (0.73) MAPTMGAMKDM4EGAASI
SCHEMBL1638634 0.91 PIK3CG (0.61) MAPTMGAMKDM4EGAASI
SCHEMBL12766910 0.91 MAPT (0.73) MAPTMGAMKDM4EGAASI
SCHEMBL12767397 0.91 GUSB (0.59) MAPTMGAMKDM4EGAASI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US claimed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP claimed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO claimed
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP disclosed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 MAPT 85/4885MGAM 1174/4885KDM4E 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.